Madrigal Pharmaceuticals, Inc.

DB:YDO1 Stock Report

Market Cap: €6.7b

Madrigal Pharmaceuticals Future Growth

Future criteria checks 5/6

Madrigal Pharmaceuticals is forecast to grow earnings and revenue by 60% and 45.7% per annum respectively. EPS is expected to grow by 59.7% per annum. Return on equity is forecast to be -87.9% in 3 years.

Key information

60.0%

Earnings growth rate

59.7%

EPS growth rate

Biotechs earnings growth35.4%
Revenue growth rate45.7%
Future return on equity-87.9%
Analyst coverage

Good

Last updated17 Dec 2024

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

DB:YDO1 - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20271,7787864218719
12/31/20261,0021133645112
12/31/2025479-287-225-19614
12/31/2024168-503-530-45112
9/30/202477-519-438-431N/A
6/30/202415-510-456-449N/A
3/31/2024N/A-444-391-389N/A
12/31/2023N/A-374-326-324N/A
9/30/2023N/A-347-303-303N/A
6/30/2023N/A-330-277-277N/A
3/31/2023N/A-315-259-259N/A
12/31/2022N/A-295-225-225N/A
9/30/2022N/A-274-215-214N/A
6/30/2022N/A-256-201-201N/A
3/31/2022N/A-247-191-190N/A
12/31/2021N/A-242-184-184N/A
9/30/2021N/A-236-191-191N/A
6/30/2021N/A-231-193-193N/A
3/31/2021N/A-219-171-170N/A
12/31/2020N/A-202-158-158N/A
9/30/2020N/A-171-115-115N/A
6/30/2020N/A-134-79-78N/A
3/31/2020N/A-105-66-66N/A
12/31/2019N/A-84-42-42N/A
9/30/2019N/A-68-36-36N/A
6/30/2019N/A-55-30-30N/A
3/31/2019N/A-42-23-23N/A
12/31/2018N/A-33-26-26N/A
9/30/2018N/A-30-25-25N/A
6/30/2018N/A-30N/A-25N/A
3/31/2018N/A-32N/A-27N/A
12/31/2017N/A-31N/A-22N/A
9/30/2017N/A-30N/A-22N/A
6/30/2017N/A-36N/A-26N/A
3/31/2017N/A-31N/A-21N/A
12/31/2016N/A-26N/A-18N/A
9/30/2016N/A-21N/A-13N/A
6/30/2016N/A-8N/A-5N/A
3/31/2016N/A-7N/A-3N/A
12/31/2015N/A-7N/A-3N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: YDO1 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1%).

Earnings vs Market: YDO1 is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: YDO1 is expected to become profitable in the next 3 years.

Revenue vs Market: YDO1's revenue (45.7% per year) is forecast to grow faster than the German market (5.6% per year).

High Growth Revenue: YDO1's revenue (45.7% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: YDO1 is forecast to be unprofitable in 3 years.

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/03 14:28
End of Day Share Price 2025/01/02 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Madrigal Pharmaceuticals, Inc. is covered by 22 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Matthew LuchiniBMO Capital Markets Equity Research
Jason ZemanskyBofA Global Research
Alexandria HammondBofA Global Research